Amylyx Pharmaceuticals Stock Forecast
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMLX analyst consensus
Consensus (11 analysts)
strong_buy
Avg. price target
$43.00+65.26%
- Strong buy 0
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Amylyx Pharmaceuticals (2026-11-17), 10 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $43.00, with a high estimate of $57.00 and a low estimate of $25.00. The average target implies upside of 65.3% from the current price of $26.02.
The spread between the highest and lowest targets is 128.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AMLX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 10 | 91% |
| Hold | 1 | 9% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-11-17.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $25.00 | -3.92% |
| Average target | $43.00 | +65.26% |
| High target | $57.00 | +119.06% |